Do not use if you have ever had an allergic reaction to SOLIFENACIN VIATRIS or any of the ingredients listed at the end of the CMI. There are a number of circumstances in which a person should not use ...

Sept. 20, 2005 (Atlanta) — Results from the STAR trial, comparing two new-generation antimuscarinics solifenacin and tolterodine extended release (ER), suggest that solifenacin is superior in reducing ...

Antimuscarinics have remained the standard of care for patients with overactive bladder (OAB) syndrome for several decades, despite the fact that, owing to their adverse effects, these drugs are ...

Astellas Pharma announced results from the Phase 3b BESIDE trial of solifenacin (SOLI) with mirabegron (MIRA) as an add-on therapy in incontinent overactive bladder (OAB) patients. The BESIDE study is ...

Solifenacin (Bispec (5 mg)) is a urinary antispasmodic agent, prescribed for overactive bladder with or without incontinence.It works by blocking the action of certain chemicals in the body to help ...

Nov. 23, 2004 — The U.S. Food and Drug Administration (FDA) has approved solifenacin succinate for the treatment of overactive bladder, erlotinib as second-line therapy for locally advanced or ...

With reference to the subject mentioned above, kindly find attached media release which is self-explanatory. Request you to kindly take the same on record. Advisory Alert: It has come to our attention ...

Shares of pharma major Glenmark Pharma rose as much as 2.5 percent intraday Thursday as it has received tentative USFDA nod for Solifenacin Succinate tablets. "Glenmark Pharmaceuticals Inc., USA has ...

Solifenacin (Bispec (10 mg)) is a urinary antispasmodic agent, prescribed for overactive bladder with or without incontinence.It works by blocking the action of certain chemicals in the body to help ...